Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis
Files in This Item:
|J._Biol._Chem.-2016-Reynolds-7242-55.pdf||4.46 MB||Adobe PDF||Download|
|Title:||Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis||Authors:||Reynolds, Alison
Butler, Clare T.
Smith, Andrew J.
|Permanent link:||http://hdl.handle.net/10197/9315||Date:||1-Apr-2016||Online since:||2018-04-11T12:46:52Z||Abstract:||Retinal angiogenesis is tightly regulated to meet oxygenation and nutritional requirements. In diseases such as proliferative diabetic retinopathy and neovascular age-related macular degeneration, uncontrolled angiogenesis can lead to blindness. Our goal is to better understand the molecular processes controlling retinal angiogenesis and discover novel drugs that inhibit retinal neovascularization. Phenotype-based chemical screens were performed using the ChemBridge DiversetTM library and inhibition of hyaloid vessel angiogenesis in Tg(fli1:EGFP) zebrafish. 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol, (quininib) robustly inhibits developmental angiogenesis at 4–10 μm in zebrafish and significantly inhibits angiogenic tubule formation in HMEC-1 cells, angiogenic sprouting in aortic ring explants, and retinal revascularization in oxygen-induced retinopathy mice. Quininib is well tolerated in zebrafish, human cell lines, and murine eyes. Profiling screens of 153 angiogenic and inflammatory targets revealed that quininib does not directly target VEGF receptors but antagonizes cysteinyl leukotriene receptors 1 and 2 (CysLT1–2) at micromolar IC50 values. In summary, quininib is a novel anti-angiogenic small-molecule CysLT receptor antagonist. Quininib inhibits angiogenesis in a range of cell and tissue systems, revealing novel physiological roles for CysLT signaling. Quininib has potential as a novel therapeutic agent to treat ocular neovascular pathologies and may complement current anti-VEGF biological agents.||Funding Details:||Health Research Board
Science Foundation Ireland
|Type of material:||Journal Article||Publisher:||American Society for Biochemistry and Molecular Biology||Journal:||Journal of Biological Chemistry||Volume:||291||Issue:||14||Start page:||7242||End page:||7255||Copyright (published version):||2016 The American Society for Biochemistry and Molecular Biology||Keywords:||Angiogenesis; Drug discovery; Eye; G protein-coupled receptor (GPCR); Leukotriene; Blindness; Hyaloid vasculature development; Ocular angiogenesis||DOI:||10.1074/jbc.M115.710665||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Conway Institute Research Collection|
Biomolecular and Biomedical Science Research Collection
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.